Kate Haviland, CHIEF EXECUTIVE OFFICER at Blueprint Medicines Corp (BPMC), sold 3,096 shares at $85.47 ($268K) on 2025-04-01, disclosed to the SEC on 2025-04-03.
Scheduled sale ($268k) by CHIEF EXECUTIVE OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $85.47 | 600 | $51K | 19.1% |
| 2 | $86.14 | 598 | $52K | 19.2% |
| 3 | $86.14 | 598 | $52K | 19.2% |
| 4 | $87.34 | 1,200 | $105K | 39.1% |
| 5 | $88.59 | 100 | $9K | 3.3% |
| Total | $86.55 avg | 3,096 |
| $268K |
| 100% |
| Filing → |
| BPMC | SELL | 2024-12-03 | $396K | — | Filing → |
| BPMC | SELL | 2024-03-11 | $2.3M | — | Filing → |
| BPMC | SELL | 2023-03-08 | $597K | — | Filing → |